Telomir PharmaceuticalsTELO
TELO
About: Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.
0
Funds holding %
of 6,740 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
900% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 2
417% more capital invested
Capital invested by funds: $337K [Q1] → $1.74M (+$1.4M) [Q2]
257% more funds holding
Funds holding: 7 [Q1] → 25 (+18) [Q2]
0.95% more ownership
Funds ownership: 0.27% [Q1] → 1.22% (+0.95%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for TELO.
Financial journalist opinion
Charts implemented using Lightweight Charts™